Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. is a clinical-stage biotechnology company focused on developing RNAi-based cancer therapies. Its pipeline includes liposomal drug candidates such as prexigebersen, BP1002, BP1003, and BP1001-A, which are being studied for hematologic malignancies and solid tumors. The company has not generated significant revenue to date and remains dependent on external financing, collaborations, and eventual regulatory approval to create commercial value. In 2025, management disclosed an operational pause and broad employee furloughs as it sought funding, underscoring the company’s early-stage and cash-constrained profile.

1.15

1.15

— Bio-Path Holdings, Inc.
%
Oncology drug candidates90% Experimental cancer therapies in preclinical or clinical development for hematologic cancers and solid tumors.
Research and development services10% Internal discovery, preclinical work, and clinical trial execution supporting pipeline advancement.

Bio-Path does not sell commercial products today; its near-term counterparties are research sites, contract research...

  • Clinical research partnersprimary

    CROs, laboratories, manufacturing organizations, and trial sites that execute preclinical and clinical development work.

  • Potential licensing and collaboration partnersprimary

    Biopharma companies that may fund development, license assets, or co-develop candidates in exchange for rights.

  • Clinical trial patientssecondary

    Patients with refractory/relapsed cancers who participate in studies of BP1002, BP1003, and related programs.

  • Future commercial healthcare buyersemerging

    Hospitals, oncology practices, and payers that would buy approved therapies if any candidate reaches market.

Bio-Path is headquartered in Bellaire, Texas, and its operations are centered in the United States...

  • •Headquartered in Bellaire, Texas, United States
  • •Clinical trial activity is concentrated in U.S. research institutions
  • •No meaningful international commercial revenue disclosed
  • •U.S. capital markets are important for financing the business
  • •Geography mainly affects trial execution and funding access

Bio-Path’s strategy is to advance its oncology pipeline through preclinical work, IND-enabling studies, and clinical...

01
Secure additional capitalshort-term

The company disclosed that current cash is not sufficient to fund obligations for the next 12 months, making financing the immediate priority.

02
Advance lead oncology programsmedium-term

Pipeline progress is the main path to value creation and future partnering leverage.

03
Pursue strategic partnershipsmedium-term

Partnerships can provide non-dilutive funding and external validation for drug candidates.

Bio-Path faces substantial going-concern and dilution risk because it has minimal revenue, recurring losses, and...

critical

Insufficient liquidity / going concern

Management stated available cash and recent financing are not enough to fund obligations for the next 12 months.

Scope
Company-wide operations and pipeline continuity
Materiality
high
high

Operational pause and employee furloughs

Cost-cutting may reduce burn, but it can also impair execution, knowledge retention, and progress on development programs.

Scope
R&D execution and organizational capability
Materiality
high
high

Clinical and regulatory failure

Drug candidates may not demonstrate sufficient safety or efficacy to advance or obtain approval.

Scope
Prexigebersen, BP1002, BP1003, BP1001-A
Materiality
high
high

Capital market dependence

The company relies on equity, debt, or partnership funding and has no arranged credit facility.

Scope
Financing flexibility and dilution risk
Materiality
high
Research and development expense accruals
Affects quarterly operating loss and comparability across periods
Going-concern assessment
Can influence disclosure severity and investor perception of solvency risk
Share-based compensation and EPS
Affects per-share comparability and capital structure analysis

Propanc Biopharma, Inc.

PPCB · Pharmaceutical Preparations

BIOVIE INC.

BIVI · Pharmaceutical Preparations

BioAge Labs, Inc.

BIOA · Pharmaceutical Preparations

BIOXYTRAN, INC

BIXT · Pharmaceutical Preparations

BridgeBio Oncology Therapeutics, Inc.

BBOT · Pharmaceutical Preparations

Oncotelic Therapeutics, Inc.

OTLC · Pharmaceutical Preparations

: 11/08/2026